Carnitine Biosynthesis and Dietary Sources
L-carnitine is synthesized endogenously from lysine and methionine precursors via a five-step pathway: gamma-trimethyllysine (from lysine post-translational modification) is oxidised by gamma-trimethyllysine dioxygenase (TMLHE, 2-oxoglutarate/Fe2+ dependent) to beta-hydroxy- gamma-trimethyllysine, then sequentially via BBHP transferase (BBOX1) to L-carnitine. Dietary carnitine is acquired primarily from meat (~5 g carnitine/100g beef) and dairy; plant sources including spirulina contain negligible carnitine (~0.01 mg/100g fresh weight) but substantial lysine and methionine precursors. The plasma free carnitine concentration is maintained at 40-60 micromol/L by intestinal uptake (via SLC22A5 OCTN2), renal tubular reabsorption (OCTN2/OCTN3), and tissue stores. Carnitine deficiency (primary: SLC22A5 mutations; secondary: renal failure, anticonvulsants, dialysis) impairs FAO and causes cardiomyopathy, myopathy, and hypoketotic hypoglycaemia.
CPT1 and the Carnitine Palmitoyltransferase Shuttle
The carnitine palmitoyltransferase (CPT) system catalyses reversible esterification of long-chain fatty acyl-CoAs (LCFA-CoA) to acyl-carnitines, which are permeable to the mitochondrial inner membrane via OCTN2 and carnitine-acylcarnitine translocase (SLC25A20). CPT1 (encoded by CPT1A in liver, CPT1B in skeletal muscle, CPT1C in brain) catalyses esterification at the outer mitochondrial membrane; OCTN2/SLC25A20 shuttles acyl-carnitines across the inner membrane; CPT2 (at the inner membrane matrix side) releases acyl-CoA into the matrix for beta-oxidation (HADHA/HADHB, ACAA2, thiophorase). CPT1 is the rate-limiting and most tightly regulated step: malonyl-CoA (produced by ACC1 when AMPK is inactive) allosterically inhibits CPT1, preventing LCFA entry during anabolic (fed) states. Thus AMPK phosphorylates and inactivates ACC1, reducing malonyl-CoA and relieving CPT1 inhibition during catabolic (fasted/exercise) states.
AMPK-ACC-CPT1 Axis and Metabolic Flexibility
Metabolic flexibility is the capacity to switch between carbohydrate and fat oxidation based on nutrient availability and hormonal status. AMPK Thr172 phosphorylation in response to AMP:ATP and ADP:ATP elevation (exercise, starvation, spirulina phycocyanin) has two key downstream effects on FAO: (1) ACC1 Ser79 phosphorylation inactivates ACC, reducing malonyl- CoA synthesis and thus relieving CPT1 inhibition; (2) CPT1A Thr576 phosphorylation (via AMPK and PKA during fasting) further reduces malonyl-CoA sensitivity, enhancing FAO capacity. Spirulina PCB activates AMPK, driving the ACC1-inactivation-CPT1-relief state, increasing hepatic and skeletal muscle fatty acid uptake into mitochondria and FAO-derived ATP and ketones. Insulin (fed state) suppresses AMPK activity, allowing ACC1 activation, malonyl-CoA elevation, and CPT1 inhibition, shunting fatty acyl-CoA toward lipogenesis (FASN).
PGC-1alpha and CPT Gene Expression
The transcriptional co-activator PGC-1alpha (PPARGC1A) drives mitochondrial biogenesis and oxidative metabolism. PGC-1alpha activates PPARgamma and PPARdelta/beta, which induce CPT1A, HADHA/B, ACAA2, and the electron transport chain (NRF1/NRF2-TFAM). AMPK phosphorylates PGC-1alpha Thr177/Ser538, promoting nuclear accumulation; SIRT1 deacetylates PGC-1alpha, further enhancing activity. Thus AMPK and NAD+-SIRT1 co-activate PGC-1alpha, increasing total CPT1A expression in muscle and liver. Cold exposure, endurance training, and metabolic stressors similarly increase PGC-1alpha. Spirulina AMPK activation provides a nutrient-based means of PGC-1alpha engagement independent of exercise.
Acyl-Carnitine Species and Tissue-Specific FAO Capacity
Different acyl-carnitine species (acetyl-C2, propionyl-C3, butyryl-C4, octanoyl-C8, palmitoyl- C16, linoleoyl-C18) accumulate based on the predominant LCFA oxidised and the rate of beta-oxidation. Short- and medium-chain acyl-carnitines (C2-C10) are substrates for mitochondrial oxidation and do not require CPT1/2. Skeletal muscle and cardiac muscle have high CPT1B and sustained FAO capacity; liver has high CPT1A but uses FAO-derived acetyl-CoA primarily for ketogenesis (via HMGCS2) rather than complete oxidation. Brain tissue expresses CPT1C, which may sense LCFA-CoA status independent of FAO but rather linked to neuroprotection and autophagy regulation. Dysregulated acyl-carnitine accumulation (elevated C16:0/C18:0 ratios) is associated with insulin resistance, obesity, and type 2 diabetes.
Carnitine and Ketogenesis: The Fed-to-Fasted Transition
During fasting, AMPK activation increases hepatic FAO and CPT1A activity, driving acetyl-CoA production beyond the capacity of the TCA cycle to oxidise it (TCA cycle capacity is ~5 acetyl- CoA/min at rest; ketogenesis can consume acetyl-CoA at much higher rates). Excess acetyl-CoA is converted to ketone bodies (acetoacetate, beta-hydroxybutyrate, acetone) by HMGCS2 (3- hydroxy-3-methylglutaryl-CoA synthase 2, specific to ketogenesis) and HMG-CoA lyase (HMGCL). Circulating ketones cross the blood-brain barrier via monocarboxylate transporter (MCT1) and are oxidised by brain, muscle, and cardiac tissue via SCOT (succinyl-CoA transferase/3- oxoacid CoA-transferase, OXCT1) to regenerate acetyl-CoA for ATP production. AMPK activation by spirulina thus facilitates the transition to ketogenesis-dependent metabolism during fasting or carbohydrate restriction, improving metabolic health and neuroprotection.
Related Reading
Summary
Carnitine-mediated fatty acid oxidation is a cornerstone of metabolic flexibility and energy homeostasis. Spirulina drives this axis through AMPK-mediated phosphorylation of ACC1 (reducing malonyl-CoA inhibition of CPT1) and through PGC-1alpha activation (increasing CPT1A/HADHA/HADHB expression). The net result is increased mitochondrial LCFA import, FAO-derived ATP and NADH production, and ketogenesis-ready hepatic capacity. Spirulina also supplies lysine and methionine precursors supporting endogenous carnitine synthesis, creating a comprehensive metabolic shift from glucose-dependent to fat/ketone-dependent metabolism.